E3 Ubiquitin Ligase CHFR Regulates Lung Endothelial Barrier Integrity and Innate Immunity through Control of VE-cadherin Expression

E3 泛素连接酶 CHFR 通过控制 VE-钙粘蛋白表达来调节肺内皮屏障完整性和先天免疫

基本信息

  • 批准号:
    10706515
  • 负责人:
  • 金额:
    $ 42.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-20 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT In Project 2 we will investigate mechanistically the role of the newly discovered endothelial cell expressed ubiquitin E3 ligase CHFR (checkpoint with fork-head and ring finger domain) in regulating lung barrier integrity and the innate immune function of vascular endothelial cells. VE-cadherin (VE-cad) expressed at endothelial adherens junctions (AJs) functions as a “gatekeeper” to restrict the permeability of plasma macromolecules and influx of phagocytic neutrophils (PMNs) into tissue. However, the key mechanisms triggering the loss of VE-cad expression at AJs have remained elusive. Our Supporting Data show: 1) CHFR mediates ubiquitylation of VE-cad through K48-linked polyubiquitin (poly-Ub) chains resulting in VE-cadherin degradation, 2) genetic deletion of CHFR in human lung endothelial cells (EC) or mouse EC in vivo prevented ubiquitylation and degradation of VE-cadherin; 3) EC-specific deletion of Chfr in mice (Chfr∆EC) also significantly reduced the generation of the potent endothelial barrier-disrupting mediator angiopoietin-2 (Ang-2); 4) CHFR additionally ubiquitylated AKT1 via K48-linked poly-Ub in ECs, which reduced AKT1 expression and led to FoxO1 nuclear translocation and activation; 5) EC-specific deletion of FoxO1 (FoxO1∆EC) in mice prevented the expression of CHFR and Ang-2, and the disruption of VE-cadherin barrier; and 6) EC-specific deletion of Chfr in mice also enhanced the ability of transmigrated PMNs to phagocytose and eliminate Pseudomonas aeruginosa. Based on these exciting data, in Aim 1, we will test the hypothesis that expression of CHFR in lung ECs, downstream of TLR4 signaling, causes the loss of VE-cadherin expression at AJs secondary to ubiquitylation of VE-cadherin through K48-linked polyubiquitin chains. In Aim 2, we will test the hypothesis that TLR4-induced CHFR expression increases FoxO1-mediated Ang-2 generation to injure directly the lung endothelial barrier subsequent to ubiquitylation of AKT1. In Aim 3, we will test the hypothesis that CHFR-mediated loss of VE- cadherin at AJs induces transendothelial migration of PMNs and is thus an essential host-defense mechanism regulating bacterial elimination capacity of the transmigrated PMNs. These studies will employ a repertoire of biochemical, molecular, in vivo real-time intravital imaging, and functional assays available in the Cores to define how CHFR mediates the degradation of VE-cadherin and AKT1 through the ubiquitylation-dependent pathways and its consequences on endothelial barrier integrity and innate immune function of the lung endothelium. We will use a variety of EC-restricted knockout mouse models to accomplish the above aims. The long-term objective of these studies is to identify and develop novel therapeutic approaches targeting ARDS via manipulation of CHFR expression. Furthermore Project 2 will be directly integrated with the other Projects and help to inform the innate immune function of the lung endothelium and its role in the mechanism of inflammatory lung injury.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Asrar B. Malik其他文献

Tissue Regeneration Requires Edema Fluid Clearance by Compensatory Lymphangiogenesis in Zebrafish
斑马鱼的组织再生需要通过补偿性淋巴管生成清除水肿液
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Olamide Olayinka;Hannah Ryu;Xiaowei Wang;Asrar B. Malik;Hyun Min Jung
  • 通讯作者:
    Hyun Min Jung
H<sub>2</sub>O<sub>2</sub> and Tumor Necrosis Factor-α Activate Intercellular Adhesion Molecule 1 (ICAM-1) Gene Transcription through Distinct <em>cis</em>-Regulatory Elements within the ICAM-1 Promoter
  • DOI:
    10.1074/jbc.270.32.18966
  • 发表时间:
    1995-08-11
  • 期刊:
  • 影响因子:
  • 作者:
    Kenneth A. Roebuck;Arshad Rahman;Venkatesh Lakshminarayanan;Kilambi Janakidevi;Asrar B. Malik
  • 通讯作者:
    Asrar B. Malik
Functional role of TRPC channels in the regulation of endothelial permeability
Compensatory lymphangiogenesis is required for edema resolution in zebrafish
补偿性淋巴管生成是斑马鱼水肿消退所必需的
  • DOI:
    10.1038/s41598-025-92970-1
  • 发表时间:
    2025-03-10
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    Olamide Olayinka;Hannah Ryu;Xiaowei Wang;Asrar B. Malik;Hyun Min Jung
  • 通讯作者:
    Hyun Min Jung
The GTPase Rab1 Is Required for NLRP3 Inflammasome Activation and Inflammatory Lung Injury
GTPase Rab1 是 NLRP3 炎症小体激活和炎症性肺损伤所必需的
  • DOI:
    10.4049/jimmunol.1800777
  • 发表时间:
    2018-11
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Yuehui Zhang;Lijun Wang;Yang Lv;Chunling Jiang;Guangyu Wu;R;al O. Dull;Richard D. Minshall;Asrar B. Malik;Guochang Hu
  • 通讯作者:
    Guochang Hu

Asrar B. Malik的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Asrar B. Malik', 18)}}的其他基金

iPSC-Derived Vascularized Human Lung Organoids and Interaction Between Lung Endothelial Cells and Alveolar Epithelial Cells
iPSC 衍生的血管化人肺类器官以及肺内皮细胞和肺泡上皮细胞之间的相互作用
  • 批准号:
    10467249
  • 财政年份:
    2022
  • 资助金额:
    $ 42.91万
  • 项目类别:
Mechanisms and Treatment of SARS-CoV-2 induced Lung Endothelial Injury
SARS-CoV-2引起的肺内皮损伤的机制和治疗
  • 批准号:
    10559640
  • 财政年份:
    2022
  • 资助金额:
    $ 42.91万
  • 项目类别:
iPSC-Derived Vascularized Human Lung Organoids and Interaction Between Lung Endothelial Cells and Alveolar Epithelial Cells
iPSC 衍生的血管化人肺类器官以及肺内皮细胞和肺泡上皮细胞之间的相互作用
  • 批准号:
    10673199
  • 财政年份:
    2022
  • 资助金额:
    $ 42.91万
  • 项目类别:
E3 Ubiquitin Ligase CHFR Regulates Lung Endothelial Barrier Integrity and Innate Immunity through Control of VE-cadherin Expression
E3 泛素连接酶 CHFR 通过控制 VE-钙粘蛋白表达来调节肺内皮屏障完整性和先天免疫
  • 批准号:
    10494617
  • 财政年份:
    2022
  • 资助金额:
    $ 42.91万
  • 项目类别:
Mechanisms and Treatment of SARS-CoV-2 induced Lung Endothelial Injury
SARS-CoV-2引起的肺内皮损伤的机制和治疗
  • 批准号:
    10390863
  • 财政年份:
    2022
  • 资助金额:
    $ 42.91万
  • 项目类别:
Amplification Mechanisms of Lung Endothelial Inflammation During Acute Lung Injury
急性肺损伤期间肺内皮炎症的放大机制
  • 批准号:
    10435435
  • 财政年份:
    2021
  • 资助金额:
    $ 42.91万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10491051
  • 财政年份:
    2021
  • 资助金额:
    $ 42.91万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10701924
  • 财政年份:
    2021
  • 资助金额:
    $ 42.91万
  • 项目类别:
Ion Flux Regulation of Macrophage Plasticity in Lung Injury and Repair
肺损伤与修复中巨噬细胞可塑性的离子通量调节
  • 批准号:
    10701929
  • 财政年份:
    2021
  • 资助金额:
    $ 42.91万
  • 项目类别:
Macrophage Plasticity in Inflammatory Lung Injury
炎症性肺损伤中的巨噬细胞可塑性
  • 批准号:
    10491049
  • 财政年份:
    2021
  • 资助金额:
    $ 42.91万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 42.91万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 42.91万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 42.91万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 42.91万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 42.91万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 42.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了